Trump's pharmaceutical pricing policy puts pressure on European healthcare systems

Royalty-free stock photograph created by Toon Lambrechts and Unsplash.

Transatlantic trade tensions

The Trump administration is intensifying its pressure on European countries to raise the reference price of drugs, a strategy designed to reduce healthcare costs in the United States. The measure is causing a rift across the continent, with the United Kingdom showing signs of yielding while EU powers, including Spain, are defending their national models.

The business strategy of the administration of Donald Trump has opened a new front of tension with EuropaThis time, the focus is on the pharmaceutical sector. Washington The United States is increasing diplomatic and trade pressure on its European partners to modify their drug pricing systems, arguing that the low costs negotiated by European public healthcare systems force American consumers to subsidize innovation and development globally. The White House's objective is to link domestic prices to an international benchmark index, which, in practice, would force a general price increase across Europe to alleviate the burden on the American market.

Division on the European front

The US offensive has met with a divided response in Europa, highlighting the different post-Brexit. The Reino Unido, in its search for a preferential trade agreement with Estados UnidosThe government has shown signs of yielding to pressure from the pharmaceutical industry, which sees this policy as an opportunity to increase its profit margins. Industry sources in Londres They confirm that the British government is showing itself to be more receptive to reviewing its public procurement mechanisms, which could set a precedent for the rest of the continent.

On the contrary, the main members of the Unión Europea, with Alemania y Francia Those at the forefront have promised to maintain a firm stance. Along similar lines, España has expressed through diplomatic channels its rejection of linking its pricing system, managed through the Ministerio de Sanidadto the demands of a third country. The defense of Sistema Nacional de Salud And its ability to negotiate affordable prices is considered a red line for the Spanish government. A change of this magnitude would not only threaten the sustainability of the system, but would also directly impact the national pharmaceutical business sector, which has developed within an ecosystem of regulated prices.

Repercussions for the sector and public finances

The impact of this policy, if it were to be implemented, would be profound for European economies. For governments, it would mean a significant increase in public pharmaceutical spendingThis would put enormous pressure on already tight budgets. This situation could force cuts in other areas of public healthcare or an increase in taxes to offset the additional costs.

For Spanish companies in the sector, the scenario is complex. Although export giants like Grifols, Almirall o PharmaMar While some companies could benefit from a potential price increase in foreign markets, the pressure on the Spanish system could alter the rules of the domestic market. The national pharmaceutical industry, integrated into the European value chain, is closely following negotiations that will define the regulatory and commercial framework for the next decade, in a power struggle that pits US domestic policy against the health sovereignty of the Unión Europea.